effects of 8 h of isocapnic hypoxia with and without ␤-blockade in humans. J. Appl. Physiol. 86(6): 1897-1904, 1999.-This study investigated whether changing sympathetic activity, acting via ␤-receptors, might induce the progressive ventilatory changes observed in response to prolonged hypoxia. The responses of 10 human subjects to four 8-h protocols were compared: 1) isocapnic hypoxia (endtidal PO 2 ϭ 50 Torr) plus 80-mg doses of oral propranolol; 2) isocapnic hypoxia, as in protocol 1, with oral placebo; 3) air breathing with propranolol; and 4) air breathing with placebo. Exposures were conducted in a chamber designed to maintain end-tidal gases constant by computer control. Ventilation (V E) was measured at regular intervals throughout. Additionally, the subjects' ventilatory hypoxic sensitivity and their residual V E during hyperoxia (5 min) were assessed at 0, 4, and 8 h by using a dynamic end-tidal forcing technique. ␤-Blockade did not significantly alter either the rise in V E seen during 8 h of isocapnic hypoxia or the changes observed in the acute hypoxic ventilatory response and residual V E in hyperoxia over that period. The results do not provide evidence that changes in sympathetic activity acting via ␤-receptors play a role in the mediation of ventilatory changes observed during 8 h of isocapnic hypoxia.
ventilation; hypoxic sensitivity; high-altitude acclimatization VENTILATORY ACCLIMATIZATION to hypoxia involves a slow and progressive rise in ventilation (V E), which in turn produces a slow increase in end-tidal PO 2 (PET O 2 ), a slow decrease in end-tidal PCO 2 (PET CO 2 ), and a progressive respiratory alkalosis. These changes start within the first few hours of the acclimatization process, and during this time the rise in V E is accompanied by an increase in the peripheral chemoreflex sensitivity to acute hypoxia [acute hypoxic ventilatory response (AHVR)]. At the cessation of the hypoxic exposure, and return to either euoxic or hyperoxic conditions, V E does not immediately revert to normal but remains somewhat elevated. The mechanisms that underlie these early stages of acclimatization are not fully understood, but it has been established that the main stimulus pathway does not involve the fall in PCO 2 and rise in pH that normally accompany hypoxia. During isocapnic hypoxia, the progressive increase in V E is actually more pronounced than during poikilocapnic hypoxia (2, 19) , presumably because of the absence of a hypocapnic braking effect. Both the increase in AHVR and the increase in V E under conditions of acute hyperoxia (compared with prehypoxic values) do not depend on whether the exposure was isocapnic and poikilocapnic (18, 36) .
One possible mechanism is that changes in autonomic function underlie part of the slow respiratory adaptation to hypoxia. This notion is supported by the observation that circulating and urinary norepinephrine levels increase progressively in humans during exposure to high altitude (11, 25, 26) , and this increase has been shown to correlate with an increase in V E (1) . Although increases in circulating levels of norepinephrine can increase both V E and, more specifically, AHVR (10) , there is also substantive evidence that carotid body function may be modulated directly by its own sympathetic supply. This evidence includes the observation that electrical stimulation of the sympathetic input to the carotid body (the preganglionic sympathetic trunk) in the anesthetized cat can increase chemosensory discharge (29) . Both the human respiratory response to increases in circulating norepinephrine and the carotid body response to stimulation by norepinephrine in experimental animals may be blocked by ␤-blockade (15, 16) .
Given these observations, the hypothesis we wished to test in the present study was whether increases in ␤-receptor-mediated sympathetic activity underlie the respiratory changes that occur early in the ventilatory acclimatization to hypoxia. We studied the response to hypoxia alone by maintainence of PET CO 2 at the subject's normal air-breathing level. In particular, we studied three different aspects of the ventilatory response. First, we studied the effect of the drug on the progressive increase in V E seen during sustained hypoxia. Second, we investigated whether the elevation in V E that remains during brief periods of hyperoxia imposed within the overall hypoxic exposure could be altered by the drug. Third, we examined whether the increase in AHVR observed during prolonged hypoxia was affected by the drug.
METHODS

Subjects.
We studied 10 subjects [6 men, 4 women; ages, 23.2 Ϯ 3.3 (SD) yr; height, 181.3 Ϯ 8.4 cm; weight, 72.1 Ϯ 8.4 kg]. None of the subjects had a history of respiratory or cardiovascular disease. All subjects gave informed consent to the study. The study had been approved by the Central Oxford Research Ethics Committee.
Protocols. The protocols were designed to allow us to compare the effects of hypoxia with and without ␤-blockade. Air-breathing protocols with and without the drug served as control exposures. Overall, the volunteers were subjected to four protocols on four different days (in varied order, with protocols separated by at least 1 wk). Female subjects were only studied during the first 2 wk of their menstrual cycles, unless they were taking a contraceptive pill, because levels of
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circulating progesterone are known to affect aspects of ventilation, such as CO 2 sensitivity (12, 13) .
The conditioning associated with each protocol lasted 8 h. The four protocols were as follows. 1) Isocapnic hypoxia, in which PET O 2 was held at 50 Torr and PET CO 2 was maintained at the subject's normal prehypoxic value. Four 80-mg doses of oral ␤-blocker (propranolol) were given every 8 h, starting 16 h before the experiment began (protocol IH-P). 2) Isocapnic hypoxia, as in protocol IH-P, except that, in this protocol, placebo tablets were given in place of propranolol at the same times as in protocol IH-P (protocol IH-C). 3) Air-breathing control, in which propranolol was given as in protocol IH-P (protocol C-P). 4) Air-breathing control, in which placebo was given as in protocol IH-C (protocol C-C).
V E was measured during these protocols at intervals of 0, 1, 2, 4, 6, and 8 h after the start. At 0, 4, and 8 h, the subjects' AHVR and V E were determined under conditions of acute hyperoxia. The PET O 2 profile used for these measurements is shown in Fig. 1 . A 5-min lead-in period at a PET O 2 of 100 Torr was followed by six square waves, with PET O 2 alternating between 50 and 100 Torr and with each gas level being maintained for 1 min. After the last step, the PET O 2 was increased to 300 Torr and was maintained at that level for 5 min. PET CO 2 was kept at 1-2 Torr above the subject's normal air-breathing value for the duration of these measurements.
Experimental technique. For the main 8-h hypoxic and control exposures, individual subjects were seated inside a clear-sided experimental chamber, where they could pursue activities such as watching television or reading. Inside this chamber, the ambient PO 2 and PCO 2 could be altered. The subjects wore a nasal cannula, held in place with a nasal O 2 -therapy mask, and PET O 2 and PET CO 2 together with inspired PO 2 and PCO 2 were measured by using a mass spectrometer (Airspec QP9000, Biggin Hill, UK). Before the start of the exposures, each subject's normal PET CO 2 value was determined during a 5-min period of air breathing. During the exposure, the subjects also wore a pulse oximeter (Ohmeda Biox 3740, Louisville, KY) that served as a safety device.
At the start of the experiment, the desired end-tidal gas values were entered manually into a controlling computer that regulated the gas composition inside the chamber. Every 5 min, the computer compared the average end-tidal gas values of the previous 3 min with the desired values, and the chamber gas composition was adjusted, if necessary, to keep end-tidal values constant. The chamber and its control system have been described in more detail elsewhere (17) .
Measurements of V E in the chamber were undertaken by using a respiratory inductance plethysmograph (Studley Data Systems, Oxford, UK). For each determination of V E, a 5-min measurement period was followed by a 5-min calibration period. During the measurement period, data were collected from the inductance plethysmograph with no disturbance of the subject. During the calibration period, subjects breathed via a mouthpiece and noseclip arrangement through a turbine volume-measurement device (SensorMedics VMM series, CardioKinetics, Salford, UK) while data continued to be collected by using inductance plethysmography. The signals obtained from inductance plethysmography in the second period of 5 min could thus be calibrated by using the simultaneous measurements of respiratory volumes, and the calibration coefficients so obtained were then used to calibrate the data obtained in the first 5 min without the use of the mouthpiece and noseclip.
The responses to square waves of hypoxia to assess AHVR and to short periods of hyperoxia were measured outside the chamber by using a mouthpiece and noseclip arrangement. Respiratory volumes were sensed with a turbine volumemeasurement device. Respiratory flows and timing information were recorded with a Fleisch pneumotachograph. Gas was sampled continuously from a port close to the mouth, and inspired PO 2 and PCO 2 together with PET O 2 and PET CO 2 were measured by using a mass spectrometer (Airspec MGA3000). The subject was also connected to an electrocardiograph (Rigel cardiac monitor 302, Morden, UK) to monitor heart rate and wore a pulse-oximeter probe (Ohmeda Biox 3740) on one finger as a safety device to monitor saturation. A computer recorded the respiratory variables every 20 ms, logged the occurrence of each QRS complex from the electrocardiogram, and determined the values for PET O 2 and PET CO 2 .
Gas control was achieved by using a computer-controlled fast gas-mixing system (20) . The required inspiratory gas composition was derived from a combination of a prediction of values from a model of the cardiorespiratory system and a breath-by-breath correction of the deviation of the actual values from the measured values. This prediction-correction scheme has been described in more detail elsewhere (32) .
Model fitting. Numerical values for AHVR were obtained by fitting a model of the ventilatory response to acute hypoxia to the data obtained during the square waves of hypoxia. The particular model employed was model 3 of Clement and Robbins (9) . In this model, total V E has been represented as the sum of ventilation at 100% saturation (V c ), which has generally been ascribed to the central chemoreflex, and a ventilation which has been ascribed to the peripheral chemoreflex (V p ). In the present experiments, PET CO 2 was maintained constant; therefore, V c may be considered constant. Under conditions of both steady PET CO 2 and steady PET O 2 , V p would be equal to G p (1 Ϫ S), where the gain term G p is the hypoxic sensitivity at the fixed PET CO 2 , representing the slope of the increase in V E with a decrease in saturation (S). Therefore, under these conditions, V Eϭ V c ϩ G p (1 Ϫ S). However, under the conditions of dynamic hypoxic stimulation that we have been studying, it is also necessary to take into account the time constant () that represents the time V E takes to move toward a new steady-state value when the Fig. 1 . Protocol used to measure hypoxic sensitivity and ventilation (V E) during hyperoxia: 5 min at end-tidal PO 2 (PET O 2 ) ϭ 100 Torr, followed by six 1-min steps alternating between PET O 2 ϭ 50 and 100 Torr and 5 min at PET O 2 ϭ 300 Torr. End-tidal PCO 2 (PET CO 2 ) was held at 1-2 Torr above subject's normal air-breathing value for the whole protocol. 
By assuming that S (t Ϫ t d ) remains constant from the beginning to the end of individual breaths, the equation may be solved to yield V E for breath i, as a function of the input (S), the parameters of the model, and the value of V E for breath i Ϫ 1.
The parameters of this model are V c , G p , , and t d . These parameters were estimated by nonlinear regression by using the Numerical Algorithms Group (Oxford, UK) Fortran library routine E04FDF to minimize the sum of squares of the residuals. S was calculated from the measured PET O 2 values by using the hemoglobin dissociation function as described by Severinghaus (35) . Statistical analysis. The main variables of interest were the values for V E in hypoxia or euoxia in the chamber (averages over the last 4 min of the 5-min measurement period were used), the values for V E in hyperoxia (averages over the last 3 min of the 5-min measurement period were used), and the values for G p and V c from the model fitting. ANOVA was used to test for significant differences between the responses to the four protocols. The particular factor of interest in the ANOVA was the interaction between drug, hypoxia, and time, because this addresses the question of whether the drug significantly altered, over time, the response of the respective variables to hypoxia.
RESULTS
All 10 subjects completed the study successfully, although some suffered from headaches during the second half of the hypoxic exposures.
Effectiveness of ␤-blockade. Table 1 shows the heart rate response at various time points for the four protocols. It can be seen that ␤-blockade of the heart was effective, as heart rate was always substantially lower than in the placebo protocols (ANOVA, P Ͻ 0.001).
End-tidal gas values before and during protocols.
Values for air-breathing PET CO 2 at the beginning of the experimental day were slightly but significantly (P Ͻ 0.05) lower in the presence of propranolol than when placebo had been taken (means Ϯ SD of 5-min averages of breath-by-breath end-tidal values: propranolol protocols, 37.7 Ϯ 4.5 Torr; placebo protocols, 39.1 Ϯ 4.0 Torr). Values are means Ϯ SE; n, 10 subjects. Heart rate with propranolol significantly lower than with placebo; P Ͻ 0.001, ANOVA. V E during hypoxia. Figure 2A shows the ventilatory response to the four protocols, as measured by inductance plethysmography in the chamber. Interestingly, no initial effect of hypoxia on V E was apparent in these subjects, although this may simply be the result of rather high values for V E at t ϭ 0 in the chamber (compare t ϭ 0 values with the remainder for the euoxic protocols). Nevertheless, V E did increase with time during the hypoxic exposures (circles) but not during the air control experiments (squares). However, there was no significant difference between the response in the presence of propranolol (closed symbols) and in the presence of placebo (open symbols), during either the hypoxic exposure or the air control.
V E during acute hyperoxia. Table 2 shows the mean V E responses to the hyperoxic exposure during the last 3 min of the test. These values are somewhat higher than those observed under hypoxic conditions within the chamber. In part, this reflects the fact that the hyperoxic data were obtained at a somewhat higher PET CO 2 than the hyperoxic data were, but it may also be related to the different techniques used to determine V E under the two conditions (inductance plethysmography in hypoxia and turbine flowmeter with mouthpiece and noseclip in hyperoxia). It can be see that in both hypoxic protocols, V E was elevated at 4 and 8 h (ANOVA, hypoxia by time, P Ͻ 0.001). On inspection of the data, there appeared to be a difference in general baseline between the four protocols. This was confirmed by ANOVA (hypoxia by drug, P Ͻ 0.05). However, there was no significant effect for the interaction between drug, hypoxia, and time, i.e., the drug did not affect the response over time to hypoxia.
V E during square waves of hypoxia. Figure 3 shows a typical breath-by-breath individual response to the square waves of hypoxia used to assess AHVR and the subsequent period of hyperoxia. In this figure, a vigorous ventilatory response to hypoxia is shown, together with the good control over PET O 2 and PET CO 2 that was achieved by using the end-tidal forcing system. Figure  4 shows the average of the first five (in some cases 4) square waves averaged for all 10 subjects at t ϭ 0, 4, and 8 h for the four protocols. It is evident from this figure that, in both hypoxic protocols, both V E overall and the amplitude of the response to acute hypoxia were increased. Table 3 shows the corresponding values of G p , V c , , and t d obtained from the model for each protocol. Values are means Ϯ SE; n ϭ 10 subjects. Values for V E, PET CO 2 , and PET O 2 are average values for last 3 min of the 5-min hyperoxic exposure. * Significant rise in V E over time with hypoxia compared with air control; P Ͻ 0.001, ANOVA. There was a significant increase over time in hypoxic sensitivity (G p ) in both hypoxic protocols (ANOVA, hypoxia by time, P Ͻ 0.001). However, propranolol did not significantly affect the change in hypoxic sensitivity in response to hypoxia over time.
V c represents V E at 100% saturation. As such, it is notable that the calculated parameter from the model follows the same pattern as V E measured during hyperoxia, as described above. Just as in the case of the measured hyperventilation during hyperoxia, V c significantly increased over time during the hypoxic exposure (ANOVA, hypoxia by time, P Ͻ 0.001), and there was a baseline difference between the protocols (ANOVA, hypoxia by drug, P Ͻ 0.05). Again, however, the drug did not significantly affect the response of V c to hypoxia over time.
Sustained hypoxia significantly increased the time constant () which indicates the time taken for V E to reach a new steady-state level after the hypoxic step (ANOVA, hypoxia by time, P Ͻ 0.05), but propranolol had no significant effect on this parameter. Conversely, hypoxia significantly decreased the time delay (t d ) (ANOVA, hypoxia by time, P Ͻ 0.05), and propranolol seemed to have the effect of increasing t d during both hypoxia and air control (ANOVA, P Ͻ 0.001) without abolishing the decrease seen during hypoxia.
DISCUSSION
The main finding of this study was that the early stages of the human ventilatory acclimatization to isocapnic hypoxia could not significantly be altered by ␤-adrenergic blockade with propranolol. In particular, the following features associated with an 8-h exposure to isocapnic hypoxia (PET O 2 ϭ 50 Torr) were all unaffected by the drug: 1) the progressive increase in V E, 2) the persistent hyperventilation observed during short spells of hyperoxia, and 3) the increase in AHVR observed during short periods in which PET O 2 was varied acutely.
Methodological considerations. Propranolol is a lipidsoluble, nonspecific, ␤-adrenergic-receptor blocker capable of crossing the blood-brain barrier. Any effects seen could, therefore, have been brought about through peripheral or central mechanisms that act at ␤ 1 -or ␤ 2 -receptors. The dose of propranolol used in this study was the same as that used in various studies of cardiorespiratory responses at altitude (1, 21, (26) (27) (28) . Bodem et al. (3) found that heart rate in humans was maximally blocked at an oral dose of propranolol of 200 mg/day, subdivided into doses given at 6-h intervals. This observation, coupled with the depression of heart rate that was observed in the present study ( Table 1) , suggests that the dose of propranolol employed was adequate for effective ␤-blockade.
Isocapnic vs. poikilocapnic hypoxia. The exposure to hypoxia that was employed in this study was isocapnic, and the question arises, To what extent are the findings likely to be applicable to hypoxic exposures in which the PET CO 2 is allowed to fall naturally, such as during travel to high altitude? As outlined in the introduction, the increases in both AHVR and residual V E under conditions of acute hyperoxia have been found to be similar, whether or not the hypoxic exposure was maintained isocapnic (18, 36) . Thus the influence (or lack thereof) of ␤-blockade is unlikely to be affected by the type of hypoxic exposure employed. More recent experiments have also found no difference between isocapnic and poikilocapnic exposures, even in the case of exposures lasting for 48 h (14, 37) . These findings have also demonstrated that the increase in V E under conditions of acute hyperoxia arises through an increase in ventilatory sensitivity to CO 2 .
Comparison with other studies in humans. We are unaware of any studies directly comparable with the one presented in this paper, in which the focus has been on the early changes in the ventilatory acclimatization to isocapnic hypoxia and in which an attempt has been made to separate out different components of the respiratory response (AHVR, hyperoxic V E) which may be mediated by different mechanisms. Two studies have investigated ventilatory changes with and without ␤-blockade during prolonged exposures to high altitude, i.e., during prolonged poikilocapnic hypoxia. Moore et al. (27) examined the ventilatory response of men to 15 days' residence at Pikes Peak (4,300 m) with and without ␤-blockade (80 mg propranolol given every 8 h). Although there were differences in metabolic rate between the two groups, the progressive fall in PET CO 2 over time between the groups was similar; this suggests that ␤-blockade did not affect the process of ventilatory acclimatization to hypoxia. Asano et al. (1) also studied men on Pikes Peak, this time for 21 days with or without the same dose of propranolol as used by Moore et al. In the study by Asano et al., V E was not altered by the drug, but the ventilatory changes were related to urinary levels of norepinephrine. Therefore, these researchers suggested that there is a close link between ventilatory and sympathetic activation during hypoxia, but that this linkage is brought about by a non-␤-adrenergic mechanism.
Although the finding is rather peripheral to the purposes of the present study, we were unable to detect any effect of ␤-blockade on the acute response to hypoxia at t ϭ 0. This is in keeping with most other studies of the effect of ␤-blockade on the acute ventilatory response to hypoxia (4, 16, 22, 30) . Only one study was able to demonstrate a significant depression of V E with ␤-blockade (100 mg bupranolol), during both air breathing and hypoxia (8) . The authors suggested that V E increased less during hypoxia when the subjects received the ␤-blocker, although this effect appears to have been small.
Other possible mechanisms related to autonomic activity. There are various other ways in which the autonomic nervous system could modulate ventilatory control during hypoxia that are not dependent on ␤-adrenergic mechanisms. These include ␣-adrenergic mechanisms, central mechanisms independent of ␣-or ␤-receptors, and parasympathetic mechanisms.
In relation to ␣-adrenergic mechanisms, in the cat there is evidence that ␣ 2 -receptors are present in the carotid body and that they exert inhibitory influences (23) . Furthermore, the inhibitory effect associated with intracarotid infusions of an ␣ 2 -receptor agonist on the carotid body appeared to be attenuated or lost after the animal had undergone a 24-to 36-h exposure to hypoxia before the infusion (6) . This suggests that there may be a downregulation of the ␣ 2 -adrenergic inhibitory mechanism during the ventilatory acclimatization to hypoxia. However, other studies in other species were unable to confirm this finding (33) . Moreover, O'Regan (29) was unable to abolish the increase in chemoreceptor discharge in response to sympathetic stimulation of the chemosensory cells with either an ␣-or a ␤-adrenergic blocker.
In relation to possible central mechanisms, adrenergic mechanisms are unlikely to play a role, because norepinephrine and epinephrine have been shown to exert a central depressant action on respiration (7). In the rat, however, it has been shown that chemoreceptor It is unlikely that slow changes in the parasympathetic input to the carotid body cause slow increases in V E during prolonged hypoxia, because parasympathetic efferents have an inhibitory influence on carotid body discharge (34, 38) , and this inhibition may be increased after prolonged exposure to hypoxia (24) .
